



CDKN2A GENE EXPRESSION/MUTATION PROGNOSIS BY COMPUTATIONAL METHODS IN THE IDENTIFICATION OF NODULAR MELANOMA

Sudheer Menon*, Shanmughavel Piramanayagam** &
Gopal Prasad Agarwal***

* Department of Surgery, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong

** Department of Bioinformatics Bharathiar University, Coimbatore, Tamilnadu, India

*** Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Hauz Khaz,
New Delhi, India

Cite This Article: Sudheer Menon, Shanmughavel Piramanayagam & Gopal Prasad Agarwal, “CDKN2A Gene Expression/Mutation Prognosis by Computational Methods in the Identification of Nodular Melanoma”, International Journal of Scientific Research and Modern Education, Volume 7, Issue 1, Page Number 11-22, 2022.

Copy Right: © IJSRME, 2022 (All Rights Reserved). This is an Open Access Article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction:

Mutations in the *CDKN2A* gene are the extremely common alteration in genetic melanoma, with presence in 40% of families with strong family ancestor. This gene normally encodes the p16 protein, which then at that point inhibits cycling-dependent kinase (CDK) 4 and 6, and the p14^{ARF} protein. Afterwards mutations in *CDKN2A* bring about hyper phosphorylation of retinoblastoma protein (RB1), releasing the E2F1 transcription factor to produce cell cycle progression from G1 to S phase. Moreover, loss of p14^{ARF} function advances the ubiquitination of p53, meanwhile diminishing cell cycle arrest and apoptosis.

Those with the *CDKN2A* mutation have been displayed to develop multiple melanomas and importantly more dysplastic nevi, including presentations consistent with dysplastic nevus syndrome. Amazingly, one study found *CDKN2A* penetrance varied with geographic location, postulating a correlation with UV exposure as biggest penetrance by age 80 in families from Australia. Histological look into *CDKN2A*-mutated familial melanomas revealed a greater association with the superficial spreading subtype as compared with *CDKN2A*-wild type familial melanomas. In addition, in a Swedish study, familial melanoma cases with the *CDKN2A* mutation were related with a younger age at onset and worse survival than those without the mutation. That study revealed that deregulation of the cell cycle with *CDKN2A* mutations may exacerbate mutational load and increase tumor aggression.

Approximately 8–12% of melanomas are diagnosed in individuals with a hereditary predisposition. Individuals with minimum one first-degree relative with melanoma have an approximately two-fold increased risk of adopting this disease, and the risk increases with the number of affected relatives. Multiple primary melanomas (MPM) produce in about 5% of sporadic melanoma infectants and in up to 19% of melanoma infectants with a strong positive family history. *CDKN2A* is well-known high-risk melanoma susceptibility gene, diagnosed about 20 years ago. Germline mutations of the *CDKN2A* gene are displayed in 20% of familial melanoma (FM) infectants, with the frequency increasing to 40% in families with three or can be more affected members.

Recently, the invention of next-generation sequencing methodologies led to the diagnosis of new melanoma susceptibility genes implicated in different unknown pathways. The telomere-shelterin *POT1* gene was diagnosed as a new high-penetrance susceptibility gene for FM and the p.S270N germline variant has been noticed as a founder mutation in Italy with a frequency in comparison with that of *CDKN2A* mutations. Two extra genes encoding proteins of the shelterin complex, *ACD* and *TERF2IP*, have been relate with familial melanoma.

Moreover, to high-risk susceptibility genes, the importance of intermediate-risk genes, such as *MC1R*, has been highlighted by candidate gene and genome-wide association studies. *MC1R* variants are classified as red hair color or ‘R’ variants and non-RHC or ‘r’ alleles according to the strength of association with the RHC phenotype. *MC1R* variants have been associated with melanoma risk that appears to be stronger in RHC carriers and in darkly pigmented patients. More recently, the E318K substitution in the *MITF-M* gene has been reported as conferring an intermediate risk for melanoma and as a susceptibility gene for renal cell carcinoma. Development of MPM, increased nevus count and no blue eye color are clinical characteristics of *MITF* E318K mutation carriers.

Hereditary susceptibility to cutaneous melanoma has been discovered in Italian high-hazardous melanoma patients from various geographical regions. *CDKN2A* has been seprated in almost all published investigations. In the current study, we did a mutational analysis of the major known melanoma susceptibility genes (*CDKN2A*, *CDK4* exon 2, *POT1* p.S270N, *MC1R*, *MITF* exon 10, and the *TERT* promoter) in high-

hazardous FM and sump patients from Central Italy and asserted the association of mutational status with the center pathological attributes of patients and tumors.

Key Words: CDKN2A, Gene Expression, Nodular Melanoma, Mutation, Computational

Methods:

Computational Methods:

Genomic DNA was extricated from entire blood utilizing a QIAamp DNA-blood midi pack (Qiagen, Hilden, Germany). Mutational screening of exons 1 α , 1 β , 2, and 3, including the exon–intron limits of CDKN2A, exon 2 of CDK4, advertiser district of the TERT quality (from –497 bp to the ATG start site), exon 10 of MITF, and the whole open perusing edge of MC1R, was performed by PCR and direct sequencing on a 3500 Genetic-Analyzer (Thermo-Fisher, Foster City, California, USA). Exhaustively, PCR enhancement of the districts of interest was acted in a Gene-Amp PCR-System 9700 utilizing the groundworks recorded in Table S1. PCR tests were led utilizing 1.25 U of AmpliTaq Gold-360 in a 50- μ l volume, containing the $\times$ 1 response support given by the producer, 1.6 mmol/l of MgCl₂, 200 μ mol/l of every de-oxynucleoside triphosphate, 0.2 μ mol/l of every preliminary, and 100 ng genomic DNA layout. Five percent dimethyl sulfoxide was added to the response arrangement. PCR enhancement conditions were as per the following: 95°C for 7 min, 35 patterns of 94°C for 1 min, T_m (°C) (Table S1) for 1 min, and 72°C for 1 min, trailed by a last expansion venture at 72°C for 7 min. Genotyping assay of the g.124493086C>T (p.S270N) mutation of the POT1 gene was carried out using TaqMan SNP Genotyping Assays (Thermo-Fisher). PCRs containing 30 mg of DNA, $\times$ 1 TaqMan Genotyping Master Mix; $\times$ 1 TaqMan genotyping assay mix, and water to reach the final volume of 10 μ l were performed in 96-well plates using the standard TaqMan protocol on a 7500 Fast Real Time-PCR System. Water controls and positive controls were run in parallel with patients' DNA samples.

The sickness causing capability of the join site variation c.861A>G in the MITF quality was assessed on RNA extricated from entire blood of the transporter patient and of a solid control utilizing the QIAamp RNA-blood small pack (Qiagen). All out RNA was treated with DNase I (Qiagen) to stay away from remaining genomic DNA defilement. First-strand cDNA was produced from 1 μ g of RNA with the ThermoScript RT-PCR System (Thermo-Fisher) as indicated by the makers' conventions. The whole MITF-M record (reference number NM_00248.3) was intensified utilizing groundwork sets exon-traversing (Table S1) and sequenced by the Sanger technique on a 3500 Genetic-Analyzer. All changes were affirmed by an investigation of a subsequent autonomous blood test.

Computational Prediction Analysis:

Nine computational devices were hurried to anticipate the impact of the p.T31M change on p14ARF work: SIFT, PROVEAN, SNAP, Polyphen-2, Panther, Mutation Taster, CONDEL, SNP&GO, and CADD. They depend on phylogenetic and underlying data and yield a score showing how amino corrosive replacements could adjust the protein structure. Polyphen-2 was performed with two distinctive preparing sets: HumDiv and HumVar in rendition 2.2.2. PROVEAN was utilized in adaptation 1.1 with a score cut-off of 2.5. Filter was run with an expectation cut-off of 0.05 and CADD with a perniciousness cut-off of 15 for the scaled scores. The NetPhos 2.0 bioinformatic apparatus was utilized to anticipate primary phosphorylation change on p14ARF due to the p.T31M replacement.

Results:

Patients' Characteristics:

An aggregate of 106 high-hazard melanoma patients, including 72 FM patients (40 ladies and 32 men) from 48 melanoma-inclined families and 34 spMPM patients (15 ladies and 19 men), were joined up with this review. The segment and clinical qualities of the patients and related cancers are recorded in table beneath:

Table 1: Demographic and clinical characteristics of melanoma patients and histo pathological features of tumors

	n (%)		
	FM	spMPM	P
Characteristics of patients	N = 72	N = 34	
Sex			
Males	32 (44.4)	19 (55.9)	0.30
Females	40 (55.6)	15 (44.1)	
Age at diagnosis			
Age (years) [mean (range)]	49 (15–81)	41 (19–80)	0.09
≤ 40	22 (30.6)	16 (47.1)	0.13
> 40	50 (69.4)	18 (52.9)	
Nevus count			
≤ 50	41 (56.9)	12 (35.3)	0.08
> 50	28 (38.9)	19 (55.9)	
Clinically atypical nevi			

Yes	18 (25.0)	7 (20.6)	1.00
No	49 (68.1)	20 (58.8)	
Skin type			
I	7 (9.7)	4 (11.8)	0.68
II	40 (55.6)	16 (47.1)	
III	23 (31.9)	13 (38.2)	
IV	2 (2.8)	1 (2.9)	
Hair color			
Red/blond	15 (20.8)	11 (32.3)	0.48
Light brown	31 (43.1)	13 (38.2)	
Dark brown/black	24 (33.3)	10 (29.4)	
Eye color			
Blue/green	36 (50.0)	15 (44.1)	0.49
Light brown	24 (33.3)	11 (32.3)	
Dark brown/black	10 (13.9)	8 (23.5)	
History of NMSC			
Yes	9 (12.5)	1 (2.9)	0.16
No	59 (81.9)	32 (94.1)	
Number of primary melanomas			
Single	58 (80.6)	NA	NA
Multiple	14 (19.4)	34 (100)	1.00
Two melanomas	13 (18.1)	30 (88.2)	
Three melanomas	1 (9.7)	2 (5.9)	
Four melanomas	0 (0)	1 (2.9)	
Five melanomas	0 (0)	1 (2.9)	
Characteristics of tumors	N = 87	N = 75	
Breslow thickness			
In situ	32 (36.8)	37 (49.3)	0.20
Invasive	50 (57.5)	37 (49.3)	
≤ 1 mm	70 (80.5)	64 (85.3)	1.00
> 1 mm	12 (13.8)	10 (13.3)	
Median value (range)	0.57 (0.22–5.00)	0.60 (0.17–2.66)	0.24
Histopathological subtype			
SSM	74 (85.1)	72 (96.0)*	NA*
NM	0 (0)	2 (2.6)	
LM/LMM	6 (6.9)	1 (1.3)	
ALM	3 (3.4)	0 (0)	
Others	3 (3.4)	0 (0)	
Anatomical site of melanoma			
Head	7 (8.0)	2 (2.6)	< 0.01
Trunk	33 (37.9)	47 (62.7)	
Extremities	42 (48.3)	26 (34.7)	
Palms or soles	3 (3.4)	0(0)	
Axial	40 (46.0)	49 (65.3)	0.02
Extremities	45 (51.7)	26 (34.7)	

ALM, acral lentiginous melanoma; FM, familial melanoma; LM/LMM, lentigo maligna/lentigo maligna melanoma; NA, not pertinent; NM, nodular melanoma; NMSC, nonmelanoma skin disease; spMPM, irregular different essential melanoma; SSM, shallow spreading melanoma. As far as the quantity of influenced people inside families, 38/48 (79%) families had two influenced individuals and the excess (10/48, 21%) had in excess of two influenced patients (five families with three influenced individuals, three with four individuals, one with five individuals, and one with six individuals). With respect to the level of relatedness, 33/48 (69%) families had first-degree influenced family members and 15/48 (31%) families had second-degree influenced family members. Among the FM patients, 58/72 (81%) introduced a solitary melanoma, though 14/72 (19%) were determined to have MPM (13 patients with two melanomas and one with three melanomas) for a sum of 87 melanoma lesions. The middle time of melanoma beginning was 49 (territory: 15–81) a long time. Age at melanoma finding was fundamentally more youthful in FM patients with MPM (40 years) than in FM patients with a solitary melanoma (50 years, $P=0.04$) (information not shown).

Concerning spMPM patients, 30/34 (88%) were determined to have two melanomas, 2/34 (6%) with three melanomas, 1/34 (3%) with four, and 1/34 (3%) with five melanomas, for an aggregate of 75 melanoma lesions. The middle age at first melanoma conclusion in spMPM patients was 41 (19–80) a long time. spMPM patients grew only melanomas of the SSM subtype contrasted and FM patients ($P=0.03$). Melanomas were all the more oftentimes situated on the limits in FM patients and on the storage compartment in spMPM patients ($P<0.01$).

Mutational Analysis:

Familial Melanoma:

Generally, we identified 4 CDKN2A germ line missense transformations in exon 2, p.V59A (c.222T>C), p.N71I (c.212A>T), p.H83Q (c.295C>A), and p.114L (c.387C>T), in six FM patients from four families, all with first-degree influenced family members and one novel nucleotide change with obscure capacity in exon 1 β , p.T31M (c.92C>T)

CDKN2A transformations, the TERT polymorphism, and MC1R variations in familial melanoma and irregular various essential melanoma patients.

				FM (N = 72) [n (%)]	spMPM (N = 34) [n (%)]
CDKN2A					
Genomic region	Nucleotide change	Effect on p16 ^{INK4A}	Effect on p14 ^{ARF}		
Exon 1β	c.92C > T	None	p.T31M	1	
Exon 2	c.214G > T	p.S56I	p.Q70H		1
Exon 2	C.222T > C	p.V59A	none	2	
Exon 2	c.212A > T	p.N71I	p.Q85H	1	
Exon 2	c.295C > A	p.H83Q	none	1	
Exon 2	c.387C > T	p.P114L	A128V	2	
Exon 2	C.442G > A	p.A148T	None	12 (16.7)	3 (8.8)
3'UTR	*500C > G	NA	NA	31 (43.1)	10 (29.4)
3'UTR	*540C > T	NA	NA	8 (11.1)	9 (26.5)
TERT					
rs2853669	c.-245T > C			42 (58.3)	16 (47)
MC1R					
Wild type				25 (34.7)	7 (20.6)
Any variant				47 (65.3)	27 (79.4)
One variant				23 (31.9)	15 (44.1)
Two variants				24 (33.3)	12 (35.3)
Any RHC variants				30 (41.7)	15 (44.1)
Any NRHC variants				17 (23.6)	12 (35.3)


FM, familial melanoma; NA, not applicable; NRHC, nonred hair color; RHC, red hair color; spMPM, sporadic multiple primary melanoma.

The clever replacement c.92C>T, bringing about the p.T31M replacement of p14ARF protein, was distinguished in the list patient of a family with three first-degree influenced members. To evaluate the pathogenic job of this variation in p14ARF, we utilized nine computational impact forecast apparatuses, acquiring a general precision of 62%. Six out of nine expectation instruments assessed the change as nonpartisan, not influencing p14ARF work, though the action indicator SIFT, the MAPP device, and the most recent and presently best reasonable CADD device ascribed a harming impact to this variation with low scores. We additionally did a primary in silico examination to investigate the likely inclusion of the T31 site in p14ARF phosphorylation. NetPhos 2.0 outcomes demonstrated that p14ARF contains three serines and one threonine as potential phosphorylation locales. Strangely, T31 is remembered for the forecast, with a high score of 0.921, yielding a logical phosphorylation site and proposing a likely impact of the T31M adjustment in p14ARF post-translational change.

CDKN2A changes were recognized all the more habitually in individuals from families with in excess of two influenced individuals than in people of families with two influenced individuals ($P=0.04$) (Table S2). A critical relationship for the presence of CDKN2A transformations and event of NMSC, which were totally analyzed as basal cell carcinoma, was noticed ($P=0.03$) (Table S2).

Also, we found three known CDKN2A polymorphisms. The p.A148T variation in exon 2 was recognized in 12/72 (17%) FM cases and the 3'UTR area polymorphisms, *500C>G and *540C>T, in 34/72 (47%) FM cases (*500C>G in 26 patients, *540C>T in three and both *500C>G and *540C>T in five). 3'UTR

polymorphisms were altogether more incessant in patients with melanoma of the storage compartment ($P=0.02$) (Table S2).



Mutational screening of the TERT advertiser distinguished the rs2853669 polymorphism (G>C replacement at –245 bp) in 42 of 72 (58%) FM patients. No factual contrasts were found among transporters and no transporters of the polymorphism as per the qualities of patients or the facility obsessive provisions of melanomas.

None of our FM patients conveyed transformations in exon 2 of the CDK4 quality and none held onto the p.S270N change in the POT1 quality.

We recognized an equivalent transformation, p.E287E, at the third base of the main codon of exon 10 of the MITF quality in a FM patient with an individual history of renal cell carcinoma and familial event of pancreatic disease in two first-degree family members. The patient was negative for transformations in the other screened high-penetrance qualities and conveyed the TERT rs2853669 polymorphism, the 3'UTR *500C>G variation, and the V60L variation in the MC1R quality. In silico joining expectation tests for the p.E287E (c.861A>G) MITF variation, with Mutation Taster, Human Splicing Finder, and Ex-skip instruments showed that this replacement might actually change a fascinating grafting enhancer site, logical upsetting typical joining. An in-vitro investigation of the joining site variation was done by enhancing and sequencing the cDNA of the MITF-M variation acquired from the transporter patient and a sound control. No joining variations contrasting in size from the transformed record and the wild-type structure were recognized. Along these lines, we exposed the PCR items to Sanger sequencing, however no joining modification in exon 10 happened in the patient.

In the MC1R examination, we recognized 10 no equivalent variations in 47/72 (65%) FM patients, with the V60L change being the most pervasive variation (25/72, 34%), trailed by R151C (15/72, 21%) Twenty-three of 47 (49%) patients conveyed one MC1R allelic variation and 24/47 (51%) conveyed two allelic variations (six homozygotes and 18 compound heterozygotes) as far as clinical qualities, MC1R variations, primarily RHC replacements, were related with a light aggregate (skin type and hair tone, $P=0.02$ and <0.001 , separately) and with a decrease old enough at analysis ($P=0.01$) contrasted and no transporters. Moreover, a decrease old enough at analysis was additionally seen in four FM patients holding onto both a CDKN2A change and MC1R variations contrasted and patients conveying just a CDKN2A transformation (middle age 39 versus 58 years, separately), albeit the low number of the change transporters didn't permit us to perform reliable factual tests.

Table 3: Recurrence of MC1R variations as per the clinical and histopathological attributes of familial melanoma and inconsistent numerous essential melanoma patients.

FM							
	MC1R Wild-type	Any MC1R variant	P^a	RHC	P^b	NRHC	P^c
Characteristics of patients							

Total (N)				72			
n	25	47		30		17	
Age at diagnosis							
≤ 40	4 (16.0)	18 (38.3)	0.06	12 (40.0)	0.07	6 (35.3)	0.13
> 40	21 (84.0)	29 (61.7)		18 (60.0)		11 (64.7)	
Median value (range)	53 (20–81)	45 (15–80)	0.03	44 (15–77)	0.01	48 (26–80)	0.04
Skin type							
I/II	11 (44.0)	35 (74.5)	0.08	25 (83.3)	0.02	10 (58.8)	< 0.01
III/IV	12 (48.0)	12 (25.5)		5 (16.7)		7 (41.2)	
Hair color							
Red-blond	0 (0)	13 (27.7)	< 0.01	12 (40.0)	< 0.01	1 (5.9)	< 0.01
Medium	8 (32.0)	23 (48.9)		12 (40.0)		11 (64.7)	
Dark	13 (52.0)	11 (23.4)		6 (20.0)		5 (29.4)	
Eye color							
Light	11 (44.0)	25 (53.2)	0.46	15 (50.0)	0.46	10 (58.8)	0.72
Medium	7 (28.0)	17 (36.2)		12 (40.0)		5 (29.4)	
Dark	5 (20)	5 (10.6)		3 (10.0)		2 (11.8)	
Nevus count							
≤ 50	17 (68.0)	24 (51.1)	0.12	16 (53.0)	0.25	8 (47.1)	0.25
> 50	6 (24.0)	21 (44.7)		12 (40.0)		9 (52.9)	
Clinically atypical nevi							
Yes	4 (16.0)	14 (29.8)	0.25	8 (26.7)	0.51	6 (35.3)	0.40
No	19 (76.0)	30 (63.8)		20 (66.7)		10 (58.8)	
Number of family members							
2	20 (80.0)	33 (70.2)	0.41	21 (70.0)	0.53	12 (70.6)	0.41
> 2	5 (20.0)	14 (29.8)		9 (30.0)		5 (29.4)	
Number of primary melanomas							
Single	21 (84.0)	37 (78.7)	0.75	22 (73.3)	0.51	15 (88.2)	0.30
Multiple	4 (16.0)	10 (21.3)		8 (26.7)		2 (11.8)	
History of NMSC							
Yes	4 (16.0)	5 (10.6)	0.47	2 (6.7)	0.39	3 (17.6)	0.25
No	19 (76.0)	40 (85.1)		27 (90.0)		13 (76.5)	
Characteristics of melanomas							
Total (N)				87			
n	29	58		38		20	
Breslow thickness							
In situ	12 (41.4)	20 (34.5)	0.63	10 (26.3)	0.29	10 (50.0)	0.18
Invasive	15 (51.7)	35 (60.3)		25 (65.8)		10 (50.0)	
≤ 1 mm	24 (82.7)	46 (79.3)	1.00	29 (76.3)	1.00	17 (85.0)	0.82
> 1mm	3 (10.3)	9 (15.5)		6 (15.8)		3 (15.0)	
Median value (range)	0.43 (0.22–4.55)	0.68 (0.24–0.50)	0.27	0.65 (0.24–3.15)	0.45	0.85 (0.27–5.0)	0.37
Anatomical site							
Head	3 (10.3)	4 (6.9)	0.42	1 (2.6)	0.35	3 (15.0)	0.28
Trunk	10 (34.5)	23 (39.6)		15 (39.5)		8 (40.0)	
Extremities	16 (55.2)	26 (44.8)		20 (52.6)		6 (30.0)	
Palm or soles	0 (0)	3 (5.2)		1 (2.6)		2 (10.0)	
Axial	13 (44.8)	27 (46.5)	0.77	16 (42.1)	0.40	11 (55.0)	0.68
Extremities	16 (55.2)	29 (50.0)		21 (55.3)		8 (40.0)	
Histopathological subtype							
SMM	25 (86.2)	49 (84.5)	0.74	35 (92.1)	0.69	14 (70.0)	0.61
Other	3 (10.3)	9 (15.5)		3 (7.9)		6 (30.0)	

spMPM

	MC1R wild-type	Any MC1R variant	P ^a	RHC	P ^b	NRHC	P ^c
Characteristics of patients							
Total (N)				34			
n	7	27		15		12	
Age at diagnosis							
≤ 40	3 (42.9)	13 (48.2)	1.00	8 (53.3)	1.00	5 (41.7)	0.58
> 40	4 (57.1)	14 (51.8)		7 (46.7)		7 (58.3)	
Median value (range)	44 (19–78)	41 (19–80)	0.64	39 (19–80)	0.57	42 (28–67)	0.70
Skin type							
I/II	2 (28.6)	18 (66.7)	0.42	12 (80.0)	0.06	6 (50.0)	0.02
III/IV	5 (71.4)	9 (33.3)		3 (20.0)		6 (50.0)	
Hair color							
Red-blond	1 (14.3)	10 (37.0)	< 0.01	7 (46.7)	< 0.01	3 (25.0)	< 0.01
Medium	–	13 (48.2)		6 (40.0)		7 (58.3)	
Dark	6 (85.7)	4 (14.8)		2 (13.3)		2 (16.7)	
Eye color							
Light	2 (28.6)	13 (48.2)	0.06	8 (53.3)	0.22	5 (41.7)	0.12
Medium	1 (14.3)	10 (37.0)		4 (26.7)		6 (50.0)	
Dark	4 (57.1)	4 (14.8)		3 (20.0)		1 (8.3)	
Nevus count							
≤ 50	4 (57.1)	8 (29.6)	0.17	5 (33.3)	0.34	3 (25.0)	0.31
> 50	2 (28.6)	17 (63.0)		9 (60.0)		8 (66.7)	
Clinically atypical nevi							
Yes	1 (14.3)	6 (22.2)	1.00	6 (40.0)	0.35	0 (0)	0.11
No	5 (71.4)	15 (55.6)		8 (53.3)		7 (58.3)	
Number of family members							
2	NA	NA		NA		NA	
> 2	NA	NA		NA		NA	
Single	NA	NA		NA		NA	
Multiple	NA	NA		NA		NA	
History of NMSC							
Yes	0 (0)	1 (3.7)	0.62	1 (6.7)	1.00	0 (0)	0.30
No	7 (100)	25 (92.6)		13 (86.7)		12 (100)	
Characteristics of melanomas							
Total (N)				75			
n	16	59		35		24	
Breslow thickness							
<i>In situ</i>	8 (50.0)	29 (49.1)	1.00	12 (34.3)	0.37	17 (70.8)	0.14
Invasive	8 (50.0)	29 (49.1)		22 (62.9)		7 (29.2)	
≤ 1 mm	13 (81.2)	51 (86.4)	0.65	29 (82.9)	0.64	22 (91.7)	0.42
> 1mm	3 (18.8)	7 (11.9)		5 (14.3)		2 (8.3)	
Median value (range)	0.77 (0.27– 2.20)	0.60 (0.17– 2.66)	0.91	0.57 (0.17– 2.66)	0.71	0.92 (0.5– 1.45)	0.46
Anatomical site							
Head	0(0)	2 (3.4)	0.03	1 (2.9)	0.02	1 (4.2)	0.09
Trunk	6 (37.5)	41 (69.5)		26 (74.3)		15 (62.5)	
Extremities	10 (62.5)	16 (27.1)		8(22.9)		8 (33.3)	
Palm or soles	0 (0)	0(0)		0(0)		0(0)	
Axial	6 (37.5)	43 (72.9)	< 0.01	27 (77.1)	0.02	16 (66.7)	< 0.01
Extremities	10 (62.5)	16 (27.1)		8 (22.9)		8 (33.3)	
Histopathological subtype							
SMM	16 (100)	56 (94.9)	1.00	32 (91.4)	0.54	24 (100)	0.09
Other	0 (0)	3 (5.1)		3 (8.6)		0 (0)	

Numbers don't generally amount to the all out on account of missing information.

FM, familial melanoma; NA, not relevant; NMSC, nonmelanoma skin disease; NRHC, nonred hair tone; RHC, red hair tone; spMPM, irregular numerous melanoma; SSM, shallow spreading melanoma.

aP esteem determined contrasting MC1R-transformed versus MC1R wild-type licenses.

bP esteem determined contrasting RHC transporters versus MC1R wild-type patients.

cTest for direct pattern across classifications (wild sort, NRHC, RHC).

Irregular MPM:

CDKN2A was transformed in just one of 34 (3%) spMPM patients, determined to have two melanomas. Three of 34 (9%) spMPM patients conveyed the A148T polymorphism, 17 of 34 (half) conveyed somewhere around one 3'UTR polymorphism (eight conveyed *500C>G, seven conveyed *540C>T, and two conveyed the 500C>G and *540C>T polymorphisms), and 16 of 34 (47%) patients conveyed the rs2853669 polymorphism in the TERT advertiser. No huge contrasts were seen in the clinical aggregate of patients and melanoma attributes among transporters and non-arrivers of the 3'UTR or the TERT advertiser polymorphisms. We didn't identify any transformation in exon 2 of the CDK4 quality and in exon 10 of the MITF quality or the p.S270N change in the POT1 quality in our spMPM patients.

Concerning MC1R, we distinguished 16 MC1R allelic variations in 27/34 (79%) spMPM patients (Table S3), with 15/27 (56%) conveying a solitary allelic variation and 12/27 (44%) conveying two variations (one homozygote and 11 compound heterozygotes). The V60L replacement was the most predominant variation and was identified in 16/34 (47%) patients. The presence of no less than one MC1R variation, essentially RHC replacements, was related with a light aggregate (light complexion type and light hair tone, $P=0.01$ and <0.01 , separately). Transporters of RHC changes were determined all the more often to have melanoma on the storage compartment contrasted and wild-type patients ($P=0.02$).

Discussion:

We portrayed the change profile of the significant melanoma defenselessness qualities in a gathering of high-hazard patients from Central Italy. We recognized CDKN2A changes in 8.3% of melanoma families, and their commonness expanded with the quantity of influenced family members inside the family ($P=0.04$). MC1R variations were recognized in 65% of FM patients and the TERT rs2853669 advertiser polymorphism was distinguished in 58%. Another equivalent change (c.861A>G, p.E287E), not influencing the MITF exon 10 joining, was recognized in one FM patient. Among patients with spMPM, 3% conveyed CDKN2A transformations, 79% conveyed MC1R variations, and 47% conveyed the TERT rs2853669 advertiser polymorphism. None of the patients conveyed transformations in CDK4 exon 2 nor held onto the POT1 p.S270N change.

The recurrence of CDKN2A changes in melanoma families has been displayed to fluctuate extensively among various populaces relying upon gauge melanoma rate, author impacts, and determination rules of the review populace. The 8.3% transformation rate recognized in our FM patients (4/48 families) is like that revealed in certain investigations, however lower than that depicted in different examinations dissecting Italian families. Our discoveries affirm that countless influenced individuals inside the family is a solid prescient factor for CDKN2A hereditary screening. Around 80% of our families were little families, with just two influenced individuals, and just 2.6% (1/38) of them conveyed a CDKN2A transformation. This worth is in accordance with the 4% frequency rate revealed in families with two influenced family members in two enormous global investigations. We didn't track down any huge relationship between clinical components of patients or growths and CDKN2A changes as a result of the low recurrence of transformations distinguished.

Outside the familial setting, the advancement of various essential growths can be connected either to microorganism line all over again transformations or changes in low-penetrance inclining qualities. The 3% predominance of CDKN2A changes in spMPM patients in the current review is lower than the 21.4% revealed beforehand in an alternate series of spMPM patients by our gathering, where CDKN2A transformations were distinguished in three of 14 patients (G101W transformation in one patient and an interionic variation IVS2+1G>T in two patients) The higher commonness of CDKN2A transformations in the past study may be identified with the counting of the interionic variation, whose utilitarian importance is unsure and that has not been recognized in any of the patients in the current review. Low change rates were additionally found in a Spanish accomplice of spMPM patients (8.2%) and in two huge multicenter populace based examinations (2.9 and 6.9%, individually)

Our discoveries demonstrate that CDKN2A changes represent a little level of high-hazard melanoma patients in Central Italy. The low recurrence of CDKN2A transformations in our cases may be clarified by the changing impact of moderate/okay melanoma helplessness qualities, by the shortfall of an organizer transformation, or by the contribution of at this point obscure inclination qualities.

We first report a clever replacement in exon 1 β of CDKN2A, p.T31M, influencing the p14ARF protein, however not p16INK4A, in the main screened patient of a family with three first-degree influenced family members. This transformation has not been distributed beforehand or remembered for quality change information bases. Six of nine computational devices anticipated this transformation to be impartial and the other three credited a harming impact to this variation with low scores. In silico investigation showed that T31 is

probably going to be a phosphorylation site, proposing an expected impact of the T31M adjustment in p14ARF post-translational alteration.

The relationship of CDKN2A 3'UTR polymorphisms with melanoma hazard has been proposed in various case-control considers, yet no clear connection with clinical elements of patients or histopathological parts of melanoma has been found. We noticed a high recurrence of CDKN2A 3'UTR polymorphisms in FM (47%) and spMPM (half) patients, altogether higher in FM patients with melanoma on the storage compartment contrasted and patients with melanoma on other physical destinations ($P < 0.01$).

RS2853669 is a typical and possibly practical polymorphism of the TERT advertiser going about as a positive controller of the TERT quality and needed for telomerase actuation during cancer movement and cell deification. This polymorphism has been distinguished as of late as a danger factor for cellular breakdown in the lungs and appears to influence endurance in intense myeloid leukemia, bladder carcinoma, renal cell carcinoma, and glioblastoma, however couple of information are accessible in melanoma. Horn et al portrayed this polymorphism to be in finished allelic linkage with the -57 bp melanoma-inclining variation of the TERT advertiser in one melanoma family and in 40% of metastatic melanoma cell lines. In our patients, a high predominance of the rs2853669 polymorphism was seen in FM (58%) and in spMPM (47%), however none of them conveyed the inclining variation at -57 bp.

A FM patient with an individual history of renal cell carcinoma and a family background of pancreatic carcinoma held onto an equivalent transformation of the MITF quality happening in the early exonic places of exon 10, the p.E287E (c.861A>G), revealed as an exceptionally uncommon variation (MAF: $G = 0.004$) in the Exome Aggregation Consortium information base. Isolation of the change with the infection was not tried as the main influenced relative was the mother, who passed on many years prior. Albeit not normal to modify the capacity of the protein, the p.E287E change presents an arrangement variety at the intron-exon limit, a fundamental district for grafting and mRNA record. It has for sure been shown that exonic single-base replacements might influence grafting while happening at restricting destinations for joining administrative components. The three computational devices (MutationTaster, Human Splicing Finder and Ex-skip) utilized for grafting expectation proposed that the p.E287E (c.861A>G) variation could almost certainly upset typical joining, modifying the enhancer site, however in-vitro useful examination did by RT-PCR and resulting Sanger sequencing couldn't identify a joining variation of MITF exon 10 brought about by the transformation. These discoveries could be clarified by the utilization of all out RNA from entire blood and not from melanocytes, in which diverse natural burdens and senescence improvements could impact the declaration of joining variations. Hence, we can't finish up whether the c.861A>G variation is an illness causing change, yet the patient's close to home and family background of numerous tumors proposes a solid hereditary part.

Mutational screening of our patients showed a high predominance of MC1R polymorphisms (65% in FM, 79% in spMPM) as seen in other Italian investigations, with the V60L being the most successive MC1R variation distinguished in FM (35%) and spMPM (47%). MC1R RHC variations were distinguished in more than 40% of both FM and spMPM patients, affirming their high predominance in melanoma patients. In our review, RHC variations were related with light phenotypic tone, supporting the job of MC1R as a significant determinant of human pigmentation.

We tracked down a huge decrease old enough at analysis in FM patients conveying MC1R variations contrasted and wild-type patients ($P = 0.03$) and the decrease became more grounded when we considered patients conveying RHC variations ($P = 0.01$). This is a questionable issue as a critical decrease old enough at finding as the number or kind of MC1R variations expanded was accounted for in little investigations including reports from Mediterranean populaces, while no affiliation was found in an enormous report on familial melanoma from three mainlands.

In CDKN2A-positive melanoma families, MC1R variations have been displayed to fundamentally expand the penetrance of CDKN2A transformations, particularly regarding numerous MC1R variations and RHC variations. We noticed the co-event of CDKN2A and MC1R replacements in four FM patients who introduced a decrease old enough at determination contrasted and FM patients with just CDKN2A transformations (39 versus 59 years).

In our spMPM associate, MC1R variations, particularly RHC changes, were common in patients with melanoma on the storage compartment. A comparable outcome was accounted for in Swedish spMPM and FM patients, while RHC variations were fundamentally connected with melanoma on the arms in a new multicenter study by the GEM bunch. Contrasts in body-site gathering and classification of MC1R variations make it hard to contrast our outcomes and those of different examinations.

The fundamental constraint of our review was the little size of our example populaces, which didn't give us sufficient measurable force in some subgroup examination. This was particularly evident when we investigated the relationship between the presence of CDKN2A changes and clinical parts of patients or histopathological elements of melanoma. In sump, we were unable to do any affiliation investigation as just a single patient had the CDKN2A transformation. Also, the two novel transformations initially recognized in our review, the replacement in exon 1β of CDKN2A, p.T31M, and the interchangeable change at the primary codon

of MITF exon 10, p.E287E, were investigated by computational devices and in-vitro grafting examination, separately, yet they should be additionally described with inside and out useful investigations.

All in all, a low recurrence of CDKN2A changes and a high commonness of MC1R variations portray high-hazard melanoma patients from Central Italy. Our outcomes support the job of CDKN2A changes in familial melanoma with in excess of two influenced individuals, and affirm the inclusion of MC1R variations in both FM and spMPM patients, with a critical relationship with decrease old enough at determination in FM patients and the event of melanoma on the storage compartment in spMPM patients. CDK4, POT1, and MITF qualities and the TERT advertiser were seldom transformed in our patients. The ID of overwhelming germline transformations in up-and-comer weakness qualities inside a particular geographic region has specific significance for counteraction and early melanoma identification to allude patients and their families to clinical screening.

Transformations in the CDKN2A quality are the most well-known modification in inherited melanoma, with presence in 40% of families with solid family ancestry. This quality encodes the p16 protein, which hinders cyclin-subordinate kinase (CDK) 4 and 6, and the p14ARF protein. Transformations in CDKN2A in this manner bring about hyperphosphorylation of retinoblastoma protein (RB1), delivering the E2F1 record factor to advance cell cycle movement from G1 to S. Also, deficiency of p14ARF work advances the ubiquitination of p53, accordingly lessening cell cycle capture and apoptosis.

Those with the CDKN2A transformation have been displayed to foster numerous melanomas and altogether more dysplastic nevi, incorporating introductions steady with dysplastic nevus condition. Curiously, one review found CDKN2A penetrance changed with geographic area, proposing a connection with UV openness as most noteworthy penetrance by age 80 in families from Australia. Histological examination of CDKN2A-changed familial melanomas uncovered a more prominent relationship with the shallow spreading subtype as contrasted and CDKN2A-wild sort familial melanomas. Moreover, in a Swedish report, familial melanoma cases with the CDKN2A change were related with a more youthful age at beginning and more regrettable endurance than those without the transformation. That study proposed that liberation of the cell cycle with CDKN2A transformations might compound mutational burden and increment cancer animosity. Then again, an Italian review partner concentrates on found no relationship of the change with more terrible endurance.

References:

1. Maria Santa Rocca, Giovanni Minervini, Andrea Di Nisio, Maurizio Merico, Maria Bueno Marinas, Luca De Toni, Kalliopi Pilichou, Andrea Garolla, Carlo Foresta, Alberto Ferlin, Identification of Rare LRP5 Variants in a Cohort of Males with Impaired Bone Mass, *International Journal of Molecular Sciences*, 10.3390/ijms221910834, 22, 19, (10834), (2021).
2. Maria Chiara Scaini, Jacopo Pigozzo, Marco Pizzi, Mariangela Manicone, Vanna Chiarion-Sileni, Pamela Zambenedetti, Massimo Rugge, Paola Zanovello, Elisabetta Rossi, Rita Zamarchi, Antonella Facchinetti, Clonal heterogeneity of melanoma in a paradigmatic case study, *Melanoma Research*, 10.1097/CMR.0000000000000510, 29, 1, (89-94), (2019).
3. Sudheer Menon (2020) "Preparation and computational analysis of Bisulphite sequencing in Germfree Mice" *International Journal for Science and Advance Research In Technology*, 6(9) PP (557-565).
4. Sudheer Menon, Shanmughavel Piramanayakam and Gopal Agarwal (2021) "Computational identification of promoter regions in prokaryotes and Eukaryotes" *EPRA International Journal of Agriculture and Rural Economic Research (ARER)*, Vol (9) Issue (7) July 2021, PP (21-28).
5. Sudheer Menon (2021) "Bioinformatics approaches to understand gene looping in human genome" *EPRA International Journal of Research & Development (IJRD)*, Vol (6) Issue (7) July 2021, PP (170-173).
6. Sudheer Menon (2021) "Insilico analysis of terpenoids in *Saccharomyces Cerevisiae*" *International Journal of Engineering Applied Sciences and Technology*, 2021 Vol. 6, Issue1, ISSN No. 2455-2143, PP(43-52).
7. Mengqi Cui, Juan Du, XiaoJun Yao, The Binding Mechanism Between Inositol Phosphate (InsP) and the Jasmonate Receptor Complex: A Computational Study, *Frontiers in Plant Science*, 10.3389/fpls.2018.00963, 9, (2018).
8. Sudheer Menon (2021) "Computational analysis of Histone modification and TFBs that mediates gene looping" *Bioinformatics, Pharmaceutical, and Chemical Sciences (RJLBPCS)*, June 2021, 7(3) PP (53-70).
9. Sudheer Menon Shanmughavel piramanayakam, Gopal Prasad Agarwal (2021) "FPMD-Fungal promoter motif database: A database for the Promoter motifs regions in fungal genomes" *EPRA International Journal of Multidisciplinary research*, 7(7) PP (620-623).
10. Sudheer Menon, Shanmughavel Piramanayakam and Gopal Agarwal (2021) Computational Identification of promoter regions in fungal genomes, *International Journal of Advance Research, Ideas and Innovations in Technology*, 7(4) PP (908-914).

11. Sudheer Menon, Vincent Chi Hang Lui and Paul Kwong Hang Tam (2021) Bioinformatics methods for identifying hirschsprung disease genes, International Journal for Research in Applied Science & Engineering Technology (IJRASET), Volume 9 Issue VII July, PP (2974-2978).
12. Sudheer Menon, (2021), Bioinformatics approaches to understand the role of African genetic diversity in disease, International Journal Of Multidisciplinary Research In Science, Engineering and Technology (IJMRSET), 4(8), PP 1707-1713.
13. Vikas Pejaver, Sean D. Mooney, Predrag Radivojac, Missense variant pathogenicity predictors generalize well across a range of function-specific prediction challenges, Human Mutation, 10.1002/humu.23258, 38, 9, (1092-1108), (2017).
14. Sudheer Menon (2021) Comparison of High-Throughput Next generation sequencing data processing pipelines, International Research Journal of Modernization in Engineering Technology and Science (IRJMETS), 3(8), PP 125-136.
15. Sudheer Menon (2021) Evolutionary analysis of SARS-CoV-2 genome and protein insights the origin of the virus, Wuhan, International Journal of Creative Research Thoughts (IJCRT), 9 (8), PP b696-b704.
16. Panagiotis Katsonis, Olivier Lichtarge, Objective assessment of the evolutionary action equation for the fitness effect of missense mutations across CAGI-blinded contests, Human Mutation, 10.1002/humu.23266, 38, 9, (1072-1084), (2017).
17. Sudheer Menon, Vincent Chi Hang Lui and Paul Kwong Hang Tam (2021) A step-by-step work flow of Single Cell RNA sequencing data analysis, International Journal for Scientific Research and Development (IJSRD), 9(6) PP 1-13.
18. Sudheer Menon (2021) Computational characterization of Transcription End sites in Human Genome, International Journal of All Research Education and Scientific Methods (IJRESM), 9(8), PP 1043-1048.
19. Sudheer Sivasankaran Menon and Shanmughavel Piramanayakam (2021) Insilico prediction of gyr A and gyr B in Escherichia coli insights the DNA-Protein interaction in prokaryotes, International Journal of Multidisciplinary Research and Growth Evaluation, (IJMRD), 2(4), PP 709-714.
20. William Bruno, Virginia Andreotti, Alessandra Bisio, Lorenza Pastorino, Giuseppe Fornarini, Stefania Sciallero, Giovanna Bianchi-Scarrà, Alberto Inga, Paola Ghiorzo, Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development, PLOS ONE, 10.1371/journal.pone.0189123, 12, 12, (e0189123), (2017).
21. Sudheer Menon, Vincent Chi Hang Lui and Paul Kwong Hang Tam (2021) Bioinformatics tools and methods to analyze single cell RNA sequencing data, International Journal of Innovative Science and Research Technology, (IJSRT), 6(8), PP 282-288.
22. Sudheer Menon (2021) Computational genome analysis for identifying Biliary Atresia genes, International Journal of Biotechnology and Microbiology, (IJB), 3(2), PP 29-33.
23. Sudheer Menon (2021) Recent Insilco advancements in genome analysis and characteristics of SARS-Cov2. International Journal of Biology Research, (IJBR), 6(3), PP 50-54.
24. Sudheer Menon (2021) Bioinformatics methods for identifying Human disease genes, International Journal of Biology Sciences, (IJBR), 3(2), PP 1-5.
25. Sudheer Menon (2021) SARS-CoV-2 Genome structure and protein interaction map, insights to drug discovery, International Journal of Recent Scientific Research, (IJSR), 12(8), PP 42659-42665.
26. Damiano Piovesan, Giovanni Minervini, Silvio C.E. Tosatto, The RING 2.0 web server for high quality residue interaction networks, Nucleic Acids Research, 10.1093/nar/gkw315, 44, W1, (W367-W374), (2016).
27. Sudheer Menon (2021) Insilico Insights to Mutational and Evolutionary aspects of SARS-Cov2, International Journal of Multidisciplinary Research and Development, (IJMRD) 8(8), 167-172.
28. Sudheer Menon (2021) Computational biology, machine learning and reverse vaccinology detects the role of conserved Nsp3 Protein and its importance in Covid-19 vaccine development, European Journal of Biotechnology and Bioscience 9(3), PP 95-99.
29. Sudheer Menon (2021) Protein Evolutionary Analysis of SARS-CoV-2 Delta Plus and C.1.2 Insights Virulence and Host Immunity, International Journal of Multidisciplinary Research and Publications (IJMRAP), 4(2), PP 6-13.
30. Sudheer Menon (2021) Computing for Genomics and Proteomics in Microbial biotechnology in the identification of SARS COV2 Variants, International Journal of Scientific Engineering and Applied Science (IJSEAS), 7(9), PP 147-175.
31. Sudheer Menon (2021) Functional Genome analysis and drug screening by Bioinformatics methods in SARS-CoV-2. International Journal of Academic Research and Development (IJARD), 6(5), PP 33-39.

32. Giovanni Minervini, Federica Quaglia, Silvio C.E. Tosatto, Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health, *Biochimie*, 10.1016/j.biochi.2015.07.009, 116, (114-124), (2015).
33. Sudheer Menon (2021) Advances in Systems biology and immunological data analysis for drug and vaccine development, *International Journal of Educational Research and Studies (IJERS)*, 3 (3), PP 53-64.
34. Sudheer Menon (2021) Whole genome sequencing and Insilico approaches to understand the genetic basis of Rare Diseases, *International Journal of Advanced Scientific Research (IJASR)*, 6(5), PP 7-13.
35. Sudheer Menon (2021) Bioinformatics approaches to identify neurodegenerative diseases by Next generation sequencing data, *International Journal of Educational Research and Development (IJERD)*, 3(3), PP 70-74.
36. Sudheer Menon (2021) Bioinformatics approaches for cross-species liver cancer analysis based single cell RNA sequencing data, *International Journal of Molecular Biology and Biochemistry (IJMBB)*, 3(1), PP 05-13.
37. Sudheer Menon (2021) Genomic sequence of worldwide strains of SARS-CoV-2: insights the Role of Variants in Disease Epidemiology, *International Journal of Advanced Research and Development (IJARD)*, 6(4), PP 14-21.
38. Sudheer Menon (2021) Differential Gene expression analysis by Single Cell RNA sequencing reveals insights to genetic diseases, *International Journal of Multidisciplinary Education and Research (IJMER)*, 6(4), PP 1-7.
39. Sudheer Menon (2021) Protein–protein interactions by exploiting evolutionary information insights the genes and conserved regions in the corresponding human and mouse genome, *International Journal of Advanced Multidisciplinary Research (IJARM)*, 8(9), PP 36-55.
40. Sudheer Menon and Binu Thomas (2021) An insights to Bioinformatics methods in Natural Product Drug Discovery, *International Journal of Clinical Biology and Biochemistry (IJCBB)*, 3(1), PP 26-37.
41. Sudheer Menon and Binu Thomas (2021) Use of multi omics data in precision medicine and cancer research with applications in tumor subtyping, prognosis, and diagnosis, *International Journal of Advanced Education and Research (IJAER)*, 6(5), PP 19-29.
42. Sudheer Menon and Binu Thomas (2021) Gene Expression Analysis, Functional Enrichment, and Network Inference in disease prediction, *International Journal of Advanced Educational Research (IJAER)*, 6(5), PP 6-18.
43. Sudheer Menon and Binu Thomas (2021) Vaccine informatics, systems biology studies on neurodegenerative diseases, *International Journal of Multidisciplinary Educational Research IJMER*, 10(9-4), PP 85-101.
44. Sudheer Menon (2021) Computational approaches to understand the role of epigenetics and microRNA in Cancer among different populations, *International Journal of Multidisciplinary Research Review (IJMDRR)* 7(9), PP 69-81.
45. Sudheer Menon and Binu Thomas (2021) Recent advances, methods and opportunities of Deep learning in computational and systems biology *International Journal of Applied and Advanced Scientific Research (IJAASR)* 6(2), PP 12-25.
46. Sudheer Menon (2021) Computational genome based studies of Complex Genetic Diseases, *International Journal of Multidisciplinary Research and Modern Education (IJMRME)* 7(2) PP 28-39.
47. Lauren G. Aoude, Michael Gartside, Peter Johansson, Jane M. Palmer, Judith Symmons, Nicholas G. Martin, Grant W. Montgomery, Nicholas K. Hayward, Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases, *Twin Research and Human Genetics*, 10.1017/thg.2015.12, 18, 02, (126-133), (2015).
48. Sudheer Menon (2021) Transcriptomic and metabolic pathway analysis reveals the mutated genes p53 and TP53 and their role in different types of cancer, *International Journal of Engineering Research and Modern Education (IJERME)*, 6(2) PP 10-33.
49. Sudheer Menon, Amanda Ramer Tait, Shanmughavel Piramanagakam, Vincent Chi Hang Lui and Paul Kwong Hang Tam (2021) Bisulphite seq data reveals host-microbiota interaction in germfree and conventional mice, *International Journal of Bioinformatics and Biological Sciences*, 9(1), PP 1-8.
50. Sudheer Menon (2021) Insilico identification of Transcription End Sites in Eukaryotes, *International Journal of Pharmacy and Biological Sciences (IJPBS)*, 11(3), PP-104-115.
51. Sudheer Menon (2021) Computational identification of upregulated genes in Breast, Prostate, and Colorectal Cancer and the Cellular Signaling process, *Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences, (RJLBPCS)*, 7(5), PP 68-83.
52. Sudheer Menon (2021) Structural and Functional Characteristics of miRNAs in colon cancer and the identification of targets by Insilco methods, *Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences, (RJLBPCS)*, 7(6), PP 86-96.

53. Panagiotis Katsonis, Amanda Koire, Stephen Joseph Wilson, Teng-Kuei Hsu, Rhonald C. Lua, Angela Dawn Wilkins, Olivier Lichtarge, Single nucleotide variations: Biological impact and theoretical interpretation, Protein Science, 10.1002/pro.2552, 23, 12, (1650-1666), (2014).